Omeros Corp (OMER)

11.66
0.47 4.20
NASDAQ : Health Care
Prev Close 11.19
Open 11.19
Day Low/High 11.19 / 11.73
52 Wk Low/High 8.90 / 30.23
Volume 304.46K
Avg Volume 369.30K
Exchange NASDAQ
Shares Outstanding 39.14M
Market Cap 429.31M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy Omeros Corp At $10, Earn 26.6% Annualized Using Options

Commit To Buy Omeros Corp At $10, Earn 26.6% Annualized Using Options

Investors eyeing a purchase of Omeros Corp stock, but cautious about paying the going market price of $11.42/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $10 strike, which has a bid at the time of this writing of $1.65.

Omeros Corporation Announces Completion Of Patient Enrollment In Pediatric Trial Of OMIDRIA®

Omeros Corporation Announces Completion Of Patient Enrollment In Pediatric Trial Of OMIDRIA®

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros (OMER) Is Today's Strong On High Volume Stock

Omeros (OMER) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Omeros (OMER) as a strong on high relative volume candidate

More Picks for a Rough Market

Let's look at other attractively valued bets in what is at least a slightly overbought market overall.

Omeros Announces Debt Financing Transaction For $20 Million In Additional Funds

Omeros Announces Debt Financing Transaction For $20 Million In Additional Funds

Omeros Corporation (NASDAQ: OMER) (the "Company") today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC ("Oxford") and East West Bank ("East West") to provide the...

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.

Omeros Corporation Reports First Quarter 2016 Financial Results

Omeros Corporation Reports First Quarter 2016 Financial Results

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Leonard M. Blum Joins Omeros To Lead Business And Commercial Activities

Leonard M. Blum Joins Omeros To Lead Business And Commercial Activities

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation Announces Exclusive Middle East Distribution Agreement For OMIDRIA®

Omeros Corporation Announces Exclusive Middle East Distribution Agreement For OMIDRIA®

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Becomes Oversold (OMER)

Omeros Becomes Oversold (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Omeros Corporation To Announce First Quarter 2016 Financial Results On May 10, 2016

Omeros Corporation To Announce First Quarter 2016 Financial Results On May 10, 2016

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation Announces Independent Studies With OMIDRIA® To Be Presented At Upcoming Ophthalmology Congresses

Omeros Corporation Announces Independent Studies With OMIDRIA® To Be Presented At Upcoming Ophthalmology Congresses

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Patient Dosing Initiated For OMS721 Phase 2 Program In Renal Diseases

Patient Dosing Initiated For OMS721 Phase 2 Program In Renal Diseases

Omeros Corporation (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases.

Commit To Purchase Omeros Corp At $10, Earn 13.8% Annualized Using Options

Commit To Purchase Omeros Corp At $10, Earn 13.8% Annualized Using Options

Investors considering a purchase of Omeros Corp shares, but tentative about paying the going market price of $16.00/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $10 strike, which has a bid at the time of this writing of 85 cents.

Omeros To Present At The 15th Annual Needham Healthcare Conference

Omeros To Present At The 15th Annual Needham Healthcare Conference

Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros (OMER) Is Today's Strong On High Volume Stock

Omeros (OMER) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Omeros (OMER) as a strong on high relative volume candidate

Omeros Corporation Initiates Its Phase 3 Program For OMS721 In AHUS Following Meeting With FDA

Omeros Corporation Initiates Its Phase 3 Program For OMS721 In AHUS Following Meeting With FDA

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation Reports Fourth Quarter And Year-End 2015 Financial Results

Omeros Corporation Reports Fourth Quarter And Year-End 2015 Financial Results

Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros To Present At The Cowen And Company 36th Annual Health Care Conference

Omeros To Present At The Cowen And Company 36th Annual Health Care Conference

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Omeros Corporation To Announce Fourth Quarter And Year-End 2015 Financial Results On March 8, 2016

Omeros Corporation To Announce Fourth Quarter And Year-End 2015 Financial Results On March 8, 2016

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Physicians Increasingly Seek Access To OMS721 Compassionate Use Program

Physicians Increasingly Seek Access To OMS721 Compassionate Use Program

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting...

Disclosure Of Omidria Post-Launch Study Findings To Occur At Hawaiian Eye And Retina Conference

Disclosure Of Omidria Post-Launch Study Findings To Occur At Hawaiian Eye And Retina Conference

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting...

Omeros is Now Oversold (OMER)

Omeros is Now Oversold (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Omeros Corp At $8, Earn 28.9% Annualized Using Options

Commit To Buy Omeros Corp At $8, Earn 28.9% Annualized Using Options

Investors considering a purchase of Omeros Corp shares, but tentative about paying the going market price of $12.32/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May put at the $8 strike, which has a bid at the time of this writing of 85 cents.

Omeros Announces $70 Million New Credit Facility And Conversion Of Contract Sales Force To In-House Team

Omeros Announces $70 Million New Credit Facility And Conversion Of Contract Sales Force To In-House Team

Omeros Corporation (NASDAQ:OMER) today announced that it has closed a non-dilutive senior credit facility with Oxford Finance and East West Bank.

Insider Trading Alert - OMER, ROVI And QTM Traded By Insiders

Insider Trading Alert - OMER, ROVI And QTM Traded By Insiders

Stocks with insider trader activity include OMER, ROVI and QTM

Insider Trading Alert - OMER, ROVI And QTM Traded By Insiders

Insider Trading Alert - OMER, ROVI And QTM Traded By Insiders

Stocks with insider trader activity include OMER, ROVI and QTM